|Description||This active molecular is a selective LTD4 antagonist. CP-85958 may become a clinical candidates for the treatment of asthma in the future.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
LY 245769 is a leukotriene E4 (LTE4) inhibitor, and it can inhibit the oxidative degradation of LTE4 and N-acetyl-LTE4 in animal model. LY 245769, as one of the...
CP-195543 is a potent and selective leukotriene B4 antagonist developed as an oral treatment for for inflammatory diseases.
Iralukast is a Leukotriene D4 receptor antagonist originated by Novartis as a a structural analogue of LTD4. It is applicated for the treatment of asthma and in...
This active molecular is a selective LTD4 antagonist. CP-85958 may become a clinical candidates for the treatment of asthma in the future.
MK-571 sodium salt hydrate
The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.
LY 292728, an oxoxanthene derivative, has been found to be a leukotriene B4 receptor antagonist that has once been studied as an antiasthmatic agent.
CP-105696, a chromen derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied against sorts of nflammatory disease.
U66858, also known as Bunaprolast, is a hydroquinone inhibitor of leukotriene synthesis, which inhibits LTB4 production in human whole blood.
This active molecular is benzophenone dicarboxylic acid derivative which is a potent BLT1 receptor antagonist. It inhibits the binding of radiolabeled-LTB4 to i...
Acebilustat, formerly known as ZK322, is an oral anti-inflammatory designed to reduce the production of leukotriene B4 (LTB4),.
Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
WAY-126299A, a benzothiazoly derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist and was once studied in A...
CP-199330, a chromen derivative, has been found to be a Leukotriene D4 receptor antagonist that was once studied against asthma by Pfizer.
LY 203647 is a a leukotriene D4 and E4 receptor antagonist with a tetrazole nucleus structure originated by Eli Lilly. No development for treatment of Ischaemic...
LY-306669, a tetrazol derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied its effect in acute lung injury.
Ono-RS-347 is an SRS-A antagonist and a new leukotriene antagonists.
ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...
Cinalukast is a selective Leukotriene D4 receptor antagonist originated by Roche and IC 50 value is 6.4 nM. Cinalukast inhibits the actions of Leukotriene D4 at...
The sodium salt form of CP-199330 which is a chromen derivative and has been found to be a Leukotriene D4 receptor antagonist that was once studied against asth...
This active molecular is a competitive leukotriene B4 receptor antagonist and IC50 value is about 100 nM. LY 255283 is selective for the BLT2 receptor, since IC...